
Monday, February 28, 2022 6:59:35 PM
https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/bat-exercises-top-up-rights-to-invest-6-3-million-resulting-in-an-increase-in-equity-position-from-18-8-to-19-5
BAT Exercises Top-Up Rights to Invest $6.3 Million Resulting in an Increase in Equity Position from 18.8% to 19.5%
MONCTON, New Brunswick — Organigram Holdings Inc. (TSX: OGI and NASDAQ: OGI), the parent company of Organigram Inc. (collectively “Organigram” or the “Company”), a leading licensed producer of cannabis, is pleased to announce that BAT has invested an additional C$6.3 million into Organigram to enhance its equity ownership position in Organigram from 18.8% to 19.5% as of December 31, 2021 by exercising its rights pursuant to an investor rights agreement (the “Investor Rights Agreement”). The Investor Rights Agreement was entered into between Organigram and BAT in connection with the formation of the Product Development Collaboration (the “PDC”) between the two companies and the strategic investment of C$221 million made by BAT in Organigram in March 2021.
The Investor Rights Agreement allows BAT periodic top-up rights to permit maintenance of its percentage ownership following certain issuances. The price per share offered to BAT is consistent with the price per share at which the relevant issuances were made subject to maximum discount requirements of the TSX.
The exempt issuances by Organigram in the three-months ended December 31, 2021 related primarily to the acquisition of Laurentian Organic Inc. pursuant to which 10,896,442 shares were issued. In addition, 83,408 shares were issued in connection with exercises of share-based compensation.
The Equity Top Up
BAT has purchased 2,659,716 common shares in Organigram at an average price of $2.3868 per share (the “Equity Top-Up”) for gross proceeds of $6,348,319 and now holds a pro-forma 19.5% equity interest based on the issued shares outstanding in Organigram of 313,477,365 as at December 31, 2021 (the end of the period in relation to which the rights were exercised) adjusted for the Equity Top-Up (310,817,649 shares outstanding plus 2,659,716 issued under the Equity Top-Up). The pro-forma equity interest as at the date hereof is 19.4%.
BAT and Organigram are approaching the first anniversary of the formation of the Product Development Collaboration (PDC) on March 10, 2021.
“Innovation is an important cornerstone of Organigram’s core strategy and the Product Development Collaboration with BAT underscores our commitment to the development of disruptive, consumer-focused cannabis products,” said Beena Goldenberg, Chief Executive Officer. “We are pleased with the successful launch of the PDC and the progress we are making so far.”
Organigram Maintains Strong Cash Position
Prior to the Equity Top-Up, Organigram enjoyed a strong cash position of C$168 million reported as at the end of Fiscal Q1-2022 (November 30, 2021). The C$6.3 million received from the Equity Top-Up further strengthens the Company’s balance sheet for general corporate purposes.
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include: Organigram Inc. and Laurentian Organic Inc., licensed producers of cannabis and cannabis-derived products in Canada, and The Edibles and Infusions Corporation, a licensed manufacturer of cannabis-infused soft chews in Canada.

Liked By
Spread the love. Be the first to like this post!
Recent OGI News
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 01/26/2023 04:18:49 PM
- Organigram Provides NASDAQ Listing Update • Business Wire • 01/26/2023 11:00:00 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 01/12/2023 12:47:58 PM
- Organigram Reports Record First Quarter Fiscal 2023 Results • Business Wire • 01/12/2023 11:00:00 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 01/05/2023 02:53:51 PM
- Organigram to Report First Quarter Fiscal 2023 Results on January 12, 2023 • Business Wire • 01/05/2023 11:00:00 AM
- Voluntary Supplemental Material Filed Pursuant to Section 11(a) of the Securities Act of 1933 by Foreign Issuers (suppl) • Edgar (US Regulatory) • 12/19/2022 04:25:43 PM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 12/09/2022 02:54:27 PM
- Organigram Wins KIND Magazine’s Cannabis Company of the Year Award and Most Innovative Product of the Year for Edison JOLTS • Business Wire • 12/08/2022 11:00:00 AM
- Three Reasons It’s Time To Get Bullish On Organigram • ValueWalk • 11/29/2022 11:51:33 PM
- Organigram Reports Record Fourth Quarter and Full Year Fiscal 2022 Results • Business Wire • 11/29/2022 01:00:00 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 11/23/2022 06:28:57 PM
- Organigram Launches HOLY MOUNTAIN to Further Support Its Strong Position in the Dried Flower and Hash Categories • Business Wire • 11/23/2022 11:00:00 AM
- High Tide Becomes Top Revenue-Generating Cannabis Company in Canada • PR Newswire (US) • 11/22/2022 11:00:00 AM
- High Tide Becomes Top Revenue-Generating Cannabis Company in Canada • PR Newswire (Canada) • 11/22/2022 11:00:00 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 11/18/2022 01:22:51 PM
- Organigram to Report Annual Fiscal 2022 Results on November 28, 2022 • Business Wire • 11/18/2022 01:00:00 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 11/17/2022 06:45:02 PM
- Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies • GlobeNewswire Inc. • 11/17/2022 01:17:09 PM
- Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies • Business Wire • 11/17/2022 01:00:00 PM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 07/14/2022 04:23:01 PM
- Organigram Reports Third Quarter Fiscal 2022 Results • Business Wire • 07/14/2022 10:00:00 AM
- Organigram to Report Third Quarter 2022 Results on July 14, 2022 • Business Wire • 07/09/2022 12:00:00 AM
- Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) • Edgar (US Regulatory) • 06/24/2022 05:42:09 PM
- Proposed Settlement Reached in 2016 Class Action • Business Wire • 06/24/2022 12:00:00 AM
1606 Corp Now Trading under Ticker CBDW, Management Announces First Acquisition • CBDW • Jan 27, 2023 11:59 AM
IQST - iQSTEL Reminds Shareholders To Get Their Votes In Before Annual Meeting Next Week On January 31, 2023 • IQST • Jan 26, 2023 9:53 AM
Nextech AR's AI-Powered CAD to Poly Toggle3D Launches Major Technology Advancements • ARWYF • Jan 26, 2023 8:46 AM
UCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023 • UCASU • Jan 26, 2023 7:21 AM
Kaya Holdings, Inc. (OTCQB: KAYS) Launches Fifth Dimension Therapeutics™ to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and Address the Growing Multi-Billion Dollar Global Psychedelics Market • KAYS • Jan 25, 2023 10:53 AM
B2 Digital's B2 SPORTS NETWORK (B2SN) Expands Distribution to Europe, Russia, and Asia with StayLIVE Agreement • BTDG • Jan 25, 2023 10:00 AM